The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions

Cancer Cytopathology

Volumn 118, Issue 2, 2010, Pages 90-96

  Hasteh, Farnaz ^a   Lin, Grace Y ^a   Weidner, Noel ^a   Michael, Claire W ^b  

^a UCSD MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cytologic effusions; Immunohistochemical markers; Malignant mesothelioma; Reactive mesothelial hyperplasia

Indexed keywords

BIOLOGICAL MARKER; DESMIN; EXCITATORY AMINO ACID TRANSPORTER 2; MUCIN 1; PROTEIN P53;

ADULT; AGED; ARTICLE; ASCITES FLUID; EPITHELIUM; FEMALE; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PLEURA EFFUSION;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; BIOLOGICAL MARKERS; DESMIN; EPITHELIUM; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; MUCIN-1; PLEURAL EFFUSION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952561875     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20071     Document Type: Article

References (21)

1. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferation. Am J Surg Pathol. 2000;24:1183-1200.
2. Bolen JW, Hammer SP, McNutt MA. Reactive and neoplastic serosal tissue. A light-microscopic, ultrastructural and immunocytochemical study. Am J Surg Pathol. 1986;10:34-47.
3. Scoones DJ, Richman PI. Expression of desmin and smooth muscle actin in mesothelial hyperplasia and mesothelioma. J Pathol. 1993;169S;188A.
4. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol. 1994;25: 753-757.
5. Wolanski KD, Whitaker D, Shilkin KB, et al. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesotheliosis. Cancer. 1998;82:583-590.
6. Attanoos, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and BCL-2. Histopathology. 2003;43:231-238.
7. Cury PM, Butcher DN, Corrin B, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelium and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol. 1999;189:251-257.
8. King J, Thatcher N, Pickering C, Haselton P. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49:561-568.
9. Afify AM, Al-Khafaji BM, Paulino AFG, et al. Diagnostic use of muscle markers in the cytologic evaluation of serous fluids. Appl Immunohistochem Mol Morphol. 2002;10:178-182.
10. Ghosh AK, Gatter KC, Dunhills MS, et al. Immunohistochemical staining of reactive mesothelium, mesothelioma and lung adenocarcinoma with a panel of monoclonal antibodies. J Clin Pathol. 1987;40:19-25.
11. Duggan MA, Masters CB, Alexander F. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin. Acta Cytol. 1987;31:807-814.
12. Bhalla R, Siddigui MT, Mandich D, et al. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol. 2007;35:342-347.
13. Walts AE, Said JW, Shintaku IP. Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: immunocytochemical and ultrastructural localization in benign and malignant cells. Diagn Cytopathol. 1987;3:41-49.
14. Shen J, Pinkus GS, Deshpande V, Cibas ES. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol. 2009;131:516-523.
15. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20: 215-220.
16. Schonherr A, Bayer M, Bocking A. Diagnostic and prognostic value of Ki67 proliferation fraction in serous effusions. Cell Oncol. 2004;26:57-62.
17. Taheri ZM, Mehrafza M, Mohammadi F, et al. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 2008;132:694-697.
18. O'Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ, Cawkwell L. Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol. 2006;45:449-453.
19. Geisinger KR, Stanley MW, Raab S, Silverman J, Abati A. Modern Cytopathology. Philadelphia, PA: Churchill Livingston; 2004:257-280.
20. Dabbs D. Diagnostic immunohistochemistry. Philadelphia, PA: Elsevier; 2006.
21. Van Muijen G, Ruiter DJ, Warnaar SO. Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest. 1987;57:359-369.